Is adalimumab a hormonal drug?

Adalimumab (Adalimumab) is a biological agent that is widely used in the treatment of a variety of chronic inflammatory diseases, but it is not a hormonal drug. It is a fully humanized monoclonal antibody that targets tumor necrosis factor α (TNF-α) and belongs to the class of anti-TNF biologics. It mainly controls chronic inflammation by blocking the overactive TNF-α signaling pathway in the body, thereby improving the condition of diseases such as rheumatoid arthritis (RA), psoriasis, active psoriatic arthritis (PA), atopic dermatitis (AD), ulcerative colitis, Crohn's disease (CD), ankylosing spondylitis and other diseases.

Hormonal drugs usually refer to glucocorticoids, such as prednisone, dexamethasone, etc., which mainly inhibit a wide range of inflammatory reactions by regulating gene transcription and are non-specific immunosuppression. Adalimumab, on the other hand, has a more precise immune intervention effect by highly selectively neutralizing TNF-α, thereby reducing the release of inflammatory cytokines. Its mechanism is more biased toward "targeted therapy" than traditional hormone therapy.

The advantage of adalimumab lies in its long-acting effect and good targeting, which reduces possible side effects of long-term use of glucocorticoids, such as osteoporosis, hyperglycemia, water and sodium retention, etc. Therefore, clinically, it is often used as a key drug in hormone reduction or replacement treatment programs. In the treatment of certain diseases such as Crohn's disease or rheumatoid arthritis, doctors often use hormonal drugs to quickly relieve symptoms in the early stages of disease control, and then gradually transition to biologics such as adalimumab to maintain long-term remission.

In summary, adalimumab is not a hormonal drug, but a targeted immunomodulator. Before receiving treatment, patients should have a professional doctor evaluate their condition and previous medication history, and develop a personalized treatment plan to maximize the benefits of the medication and reduce the risk of adverse reactions.

Reference materials:https://www.drugs.com/adalimumab.html